semaglutide medicare price reduction A New Option for Weight Loss Drugs: What Older Americans Should Know Novo Nordisk Faces 71% Medicare

Int J Obes (2012) 36(6):84354

Identification of critical IgG binding epitopes on the neonatal Fc receptor

A number of the other safety and tolerability issues associated with the GLP-1 agonists either occurred in too few patients to see numerical differences in risk between semaglutide and placebo (such as acute pancreatitis) or are events that would likely require much longer follow-up to determine risk (such as medullary thyroid cancer)

Jimnez-Jimnez FJ, Alonso-Navarro H, Garca-Martn E, Santos-Garca D, Martnez-Valbuena I, Agndez JAG

FDA-approved semaglutide drug is the first GLP-1 pill for weight loss available in the U.S., according to drugmaker Novo Nordisk